New smart drug takes aim at Hard-to-Treat cancers

NCT ID NCT06752681

Recruiting now Disease control Sponsor: Day One Biopharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose and check if the drug can shrink tumors. About 254 adults with specific cancers like ovarian, lung, or breast cancer will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical squamous cell carcinoma endometrial cancer esophageal squamous cell carcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma metastatic malignant neoplasm non-small cell lung carcinoma ovarian cancer small cell lung carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC SOLID TUMORS

Contacts and locations

Locations

Site: 001-039
RECRUITING

New York, New York, 10065, United States
Site: 001-057
RECRUITING

San Antonio, Texas, 78240, United States
Site: 001-058
RECRUITING

New Haven, Connecticut, 06511, United States
Site: 001-059
RECRUITING

Grand Rapids, Michigan, 49546, United States
Site: 001-060
RECRUITING

Avon, Indiana, 46202, United States
Site: 001-064
RECRUITING

Sarasota, Florida, 34232, United States
Site: 001-065
RECRUITING

Nashville, Tennessee, 37203, United States
Site: 001-069
RECRUITING

Houston, Texas, 77030, United States
Site: 001-073
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
Site: 011-005
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Site: 011-013
RECRUITING

Vancouver, British Columbia, V5Z 4E6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.